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Clinical Outcomes of Remote Ischemic Preconditioning Prior to
Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials
Brian Pierce, MD; Indra Bole, MD; Vaiibhav Patel, MD; David L. Brown, MD
Background-—Multiple randomized controlled trials of remote ischemic preconditioning (RIPC) prior to cardiac surgery have failed
to demonstrate clinical beneﬁt. The aim of this updated meta-analysis was to evaluate the effect of RIPC on outcomes following
cardiac surgery.
Methods and Results-—Searches of PubMed, Cochrane, EMBASE, and Web of Science databases were performed for 1970 to
December 13, 2015. Randomized controlled trials comparing RIPC with a sham procedure prior to cardiac surgery performed with
cardiopulmonary bypass were assessed. All-cause mortality, acute kidney injury (AKI), and myocardial infarction were the primary
outcomes of interest. We identiﬁed 21 trials that randomized 5262 patients to RIPC or a sham procedure prior to undergoing
cardiac surgery. The majority of patients were men (72.6%) and the mean or median age ranged from 42.3 to 76.3 years. Of the 9
trials that evaluated mortality, 188 deaths occurred out of a total of 4210 randomized patients, with 96 deaths occurring in 2098
patients (4.6%) randomized to RIPC and 92 deaths occurring in 2112 patients (4.4%) randomized to a sham control procedure,
demonstrating no signiﬁcant reduction in all-cause mortality (risk ratio [RR], 0.987; 95% CI, 0.653–1.492, P=0.95). Twelve studies
evaluated AKI in 4209 randomized patients. In these studies, AKI was observed in 516 of 2091 patients (24.7%) undergoing RIPC
and in 577 of 2118 patients (27.2%) randomized to a sham procedure. RIPC did not result in a signiﬁcant reduction in AKI (RR,
0.839; 95% CI, 0.703–1.001 [P=0.052]). In 6 studies consisting of 3799 randomized participants, myocardial infarction occurred in
237 of 1891 patients (12.5%) randomized to RIPC and in 282 of 1908 patients (14.8%) randomized to a sham procedure, resulting
in no signiﬁcant reduction in postoperative myocardial infarction (RR, 0.809; 95% CI, 0.615–1.064 [P=0.13]). A subgroup analysis
was performed a priori based on previous studies suggesting that propofol may mitigate the protective beneﬁts of RIPC. Three
studies randomized patients undergoing cardiac surgery to RIPC or sham procedure in the absence of propofol anesthesia. Most of
these patients were men (60.3%) and the mean or median age ranged from 57.0 to 70.6 years. In this propofol-free subgroup of
434 randomized patients, 71 of 217 patients (32.7%) who underwent RIPC developed AKI compared with 103 of 217 patients
(47.5%) treated with a sham procedure. In this cohort, RIPC resulted in a signiﬁcant reduction in AKI (RR, 0.700; 95% CI, 0.527–
0.930 [P=0.014]). In studies of patients who received propofol anesthesia, 445 of 1874 (23.7%) patients randomized to RIPC
developed AKI compared with 474 of 1901 (24.9%) who underwent a sham procedure. The RR for AKI was 0.928 (95% CI, 0.781–
1.102; P=0.39) for RIPC versus sham. There was no signiﬁcant interaction between the two subgroups (P=0.098).
Conclusions-—RIPC does not reduce morbidity or mortality in patients undergoing cardiac surgery with cardiopulmonary bypass. In
the subgroup of studies in which propofol was not used, a reduction in AKI was seen, suggesting that propofol may interact with
the protective effects of RIPC. Future studies should evaluate RIPC in the absence of propofol anesthesia. ( J Am Heart Assoc.
2017;6:e004666. DOI: 10.1161/JAHA.116.004666.)
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T hirty years ago, Murry et al
1
ﬁrst described ischemic
preconditioning (IPC) after observing that anesthetized
dogs subjected to prolonged circumﬂex coronary artery
occlusion and reperfusion demonstrated a marked reduction
of myocardial infarct size when exposed to 4 brief episodes of
ischemia in the circumﬂex territory separated by 5 minutes of
reperfusion prior to the prolonged occlusion. Remote IPC
(RIPC) evolved from the same in vivo canine heart model
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where ischemia-reperfusion injury could be attenuated in the
left anterior descending coronary artery distribution after
application of occlusion and reperfusion to the circumﬂex
coronary artery.2 With this ﬁnding, Przyklenk et al2 concluded
that protective mediators induced by ischemia could be
transferred to distant, “regional” cardiomyocytes. Subsequent
studies demonstrated that protection against ischemia-
reperfusion injury in humans could be extended to distant
organs, such as the kidney and brain.3,4 The discovery that
protection could be conferred by ischemia-reperfusion cycles
in distant skeletal muscle elicited invasively by rapid stimu-
lation of the gastrocnemius in rabbits5 and noninvasively by a
tourniquet in humans6 spurred widespread clinical interest.
Given that cardiac surgery has the potential for ischemia
and reperfusion injury to the heart, kidney and brain,7–9 RIPC
has long been viewed as an attractive approach to mitigate
the deleterious clinical consequences of these events. Prior
studies have shown that RIPC before cardiac surgery results
in reductions in biomarkers of renal and cardiac injury.10,11
However, randomized controlled trials (RCTs) of RIPC evalu-
ating clinical cardiovascular and renal outcomes as well as
overall mortality have not shown beneﬁt.12,13 Many of these
trials utilized propofol anesthesia, which has been shown to
negatively impact the beneﬁts of RIPC.14 With the recent
publication of the two largest trials of RIPC to date,15,16 we
performed an updated meta-analysis of RCTs to better
evaluate the clinical merit of this intervention.
Methods
Study Selection
A systematic search of published studies in any language in
the PubMed, Cochrane, EMBASE, and Web of Science
databases from 1970 to December 13, 2015, was performed
independently by two authors (V.P. and I.B.). Search terms
included remote ischemic preconditioning, cardiac surgery,
kidney injury, and renal failure, as well as combinations of
these terms. A ﬁlter for RCTs was used. Bibliographies of
retrieved articles and prior reviews on the subject were
searched for other relevant studies.
For inclusion, studies were required to be prospective
randomized trials of preoperative RIPC or a sham procedure in
patients undergoing cardiac surgery performed on cardiopul-
monary bypass. In addition, studies had to report at least one
clinical end point of interest as an outcome and enroll more
than 50 patients. Patient characteristics, study design, and
outcomes were systematically reviewed and recorded inde-
pendently by 3 authors (B.P., I.B., and V.P.). Disagreements
were resolved by consensus.
The methodological quality of each trial was evaluated
using standard criteria: method of randomization; allocation
concealment; patient, investigator, and outcome assessor
blinding; selective outcome reporting; incomplete outcome
ascertainment; and other potential sources of bias as
recommended by the Cochrane Collaboration.17 The Grades
of Recommendation, Assessment, Development, and Evalua-
tion (GRADE) approach for evaluating RCTs was applied.18
The following clinical end points were analyzed: all-cause
mortality, acute kidney injury (AKI), myocardial infarction (MI),
cerebrovascular accident (CVA), hospital length of stay (LOS),
and intensive care unit (ICU) LOS. Discrete working deﬁnitions
of AKI were reclassiﬁed as stage I, II, or III based on previous
deﬁnitions described by the Acute Kidney Injury Advisory
Group.19 Other end point deﬁnitions were those used in the
individual trials and are summarized in Table 1.20–33
Statistical Analysis
Because patient-level data from each trial were not available,
a meta-analysis of summary statistics from individual trials
was performed. Data from each trial were analyzed on an
intention-to-treat basis according to the recommendations of
the Cochrane Collaboration and the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses statement.34 Trial
results for each end point were summarized with risk ratios
(RRs) and standardized mean differences as the measures of
effect. RRs were employed because accurate time-to-event
data were not available in all trials. Summary RRs or
standardized mean differences and 95% CIs were calculated
using a random-effects model for combining results across
studies, which incorporates between- and within-study vari-
ance and provides a more conservative summary. A random-
effects model was preferred because heterogeneity across
patient characteristics and clinical trial design would be
unlikely to result in a consistent treatment effect across
trials.35 When no events were observed within a treatment
group, a 0.5 correction factor was added to all values of that
end point for calculation of the RR and its variance.36,37 To
determine whether there was heterogeneity between individ-
ual trials, we assessed the Q statistic (a weighted index of
effect estimate differences across studies assuming a v2
distribution) and I2 statistic ([Qdf]/Q9100). Because the I2
value quantiﬁes heterogeneity on a scale of 0% to 100% and
represents the extent of inconsistency among trial results
rather than a sampling error independent of the number of
studies, an I2 of ≥75% was considered representative of high
heterogeneity.38 To assess for publication bias, funnel plots
were evaluated by visual inspection and conﬁrmed by Egger’s
test.39 If analysis yielded plot asymmetry, Duval and
Tweedie’s trim and ﬁll method, a quantitative assessment of
publication bias, was performed.40
Heterogeneity was explored in subgroup analyses by study
quality (high versus low), intraoperative propofol use, additive
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European System for Cardiac Operative Risk Evaluation
(EuroSCORE), and preoperative potassium-ATP (K-ATP) antag-
onist use. Unless an anesthetic regimen without propofol was
detailed, it was assumed that propofol was administered. In
the event of protocol ambiguity, primary authors were
contacted for clariﬁcation. In trials that did not exclude
diabetic patients, it was assumed that K-ATP antagonists were
used unless speciﬁcally prohibited preoperatively. Sensitivity
analyses were performed for each outcome to determine
whether any single study disproportionately inﬂuenced the
pooled estimate by excluding individual trials one at a time
and recalculating the combined RR or standardized mean
difference for the remaining studies. P<0.05 was considered
statistically signiﬁcant and all tests were 2-sided. Statistical
analyses were performed with Comprehensive Meta-Analysis
(version 2) software (Biostat, Englewood, NJ).
Results
Literature Search
The electronic search yielded 833 citations that were
screened by reviewing the title or abstract with subsequent
removal of duplicates. Of these, 45 articles were reviewed in
full and 21 studies were included for analysis (Figure 1).
Characteristics of the studies are listed in Table 2. Eight
studies tested RIPC in patients undergoing isolated coronary
artery bypass grafting (CABG),12,20,21,23,26,29,31,41 four studies
in patients undergoing isolated valve surgery,22,24,27,33 and
the remaining 9 in patients undergoing any cardiac surgery.*
One study included additional perconditioning, the application
of short periods of ischemia and reperfusion at a distant site
delivered during target organ ischemia; only data from the
preconditioning intervention and the sham procedure were
included.22
Of the 5262 patients included in the analysis, 2624 were
randomized to RIPC and 2638 were randomized to a sham
procedure. Baseline characteristics of the study populations
showed that most patients were men (72.6%). The mean or
median ages of patients ranged from 42.3 to 76.3 years. The
majority of studies were double-blinded, randomized, and had
adequate descriptions of patient attrition. Study quality is
summarized in Table 3.
Quantitative Outcomes
Of the 188 deaths in the 4210 randomized patients under-
going cardiac surgery, 96 deaths occurred in the 2098











































































































































































































































































































































































































































































*References 3, 11, 13, 15, 16, 25, 28, 30, 32.
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occurred in the 2112 patients (4.4%) randomized to a sham
control procedure. The RR for mortality for RIPC versus sham
was 0.987 (95% CI, 0.653–1.492; P=0.95 [I2=16%]) (Fig-
ure 2A). AKI occurred in 516 of 2091 patients (24.7%)
undergoing RIPC and in 577 of 2118 patients (27.2%) who
underwent a sham procedure. The RR for AKI for RIPC versus
sham procedure was 0.839 (95% CI, 0.703–1.001; P=0.052
[I2=41%]) (Figure 2B). Postoperative MI occurred in 237 of
1891 patients (12.5%) randomized to RIPC and in 282 of 1908
patients (14.8%) randomized to a sham procedure. The RR for
MI for RIPC versus sham was 0.809 (95% CI, 0.615–1.064;
P=0.13 [I2=27%]) (Figure 2C). Postoperative CVA was diag-
nosed in 34 of 1864 patients (1.82%) who underwent RIPC
and in 37 of 1880 patients (1.97%) who underwent a sham
procedure. The RR for CVA for RIPC versus sham was 0.939
(95% CI, 0.592–1.489; P=0.79 [I2=0%]) (Figure 2D). The
standardized difference in mean ICU LOS was 0.010 days
(95% CI, 0.116 to 0.137; P=0.87 [I2=41%]) between the
1381 patients in the RIPC group and the 1396 patients in the
sham control group (Figure 2E). Similarly, the standardized
difference in mean hospital LOS was 0.026 days (95% CI,
0.091 to 0.143; P=0.67 [I2=0%]) for the 559 patients
undergoing RIPC versus 567 patients having a sham proce-
dure (Figure 2F). Summarized quantitative data for the entire
sample can be seen in Table 3.
Subgroup Analyses, Sensitivity Analyses, and
Publication Bias
Subgroup analysis showed no differences in outcomes
when compared by the use of K-ATP antagonists (results
not shown). In the subgroup of studies of patients who did
not receive propofol, we observed that most of these
patients were men (60.3%) and the mean or median age
ranged from 57.0 to 70.6 years. In this propofol-free
subgroup, 71 of 217 patients (32.7%) who underwent RIPC
developed AKI compared with 103 of 217 patients (47.5%)
treated with a sham procedure. The RR for AKI was 0.700
(95% CI, 0.527–0.930; P=0.014) for RIPC versus sham. In
studies of patients who received propofol, 445 of 1874
(23.7%) who received RIPC developed AKI compared with
474 of 1901 (24.9%) who underwent a sham procedure.
The RR for AKI was 0.928 (95% CI, 0.781–1.102; P=0.39)
for RIPC versus sham (Figure 3). Summarized quantitative
data for these subgroups can be seen in Table 4. There
was no signiﬁcant interaction between the two subgroups
(P=0.098). Additionally, there were no differences in the
effect of RIPC on development of stage I, II, or III AKI, and
there was no difference in the effect of RIPC on the
development of severe AKI, deﬁned as stage II or III AKI
(results not shown).
45 Full-text articles 
assessed for eligibility
21 Articles included in 
analysis
833 Total articles
231 PubMed articles 223 Cochrane articles 179 EMBASE articles 200 Web of Science articles
788  Articles did not meet
inclusion criteria
based on title and
abstract review or 
were duplicates
24  Full text articles excluded
3 studies had too few
patients
7 studies did not have
relevant outcomes
2 studies were not in
English
8 studies were not
specifically assessing
RIPC
4 studies were not 
cardiac surgery or 
performed on CPB
Figure 1. Study selection. Flow diagram depicts study selection for inclusion in the meta-analysis according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses.34 RIPC indicates remote ischemic preconditioning.
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Figure 2. Comparison of outcomes between remote ischemic precon-
ditioning (RIPC) and sham procedure. A, All-cause mortality. B, Acute
kidney injury. C, Myocardial infarction. D, Stroke. E, Intensive care unit
length of stay. F, Hospital length of stay. The sizes of the squares
representing the point estimates for each study are proportional to the
weight of the study. Diamonds indicate the overall risk ratio (RR) or
standardized mean difference and 95% CIs for the outcome of interest.
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Sensitivity analyses showed no signiﬁcant differences in
outcomes when results were compared by study quality
(high versus low), type of surgery performed (CABG, valve,
or mixed), severity of illness (based on additive Euro-
SCORE), or duration or site of RIPC (results not shown).
Visual inspection of the funnel plots suggested possible
publication bias (Figure 4). This was further analyzed using
the trim and ﬁll method. The RR of AKI of 0.839 (95% CI,
0.702–1.001) was unchanged by the trim and ﬁll method,
suggesting no publication bias. This was conﬁrmed by the
Egger’s test, which indicated lack of publication bias
(P=0.055).
In addition, sensitivity analyses to assess potential effects
of qualitative differences on study design and patient
selection showed that exclusion of any one trial from analysis
of mortality, AKI, MI, CVA, ICU LOS, and hospital LOS did not
change the overall ﬁndings (data not shown).
Discussion
In this meta-analysis of 5262 patients undergoing RIPC for
cardiac surgery with cardiopulmonary bypass, we found that
RIPC conferred no clinical beneﬁt. The intervention failed to
reduce the incidence of all-cause mortality, MI, CVA, and ICU
or hospital LOS. There was a strong trend towards reduction
of AKI in patients who underwent RIPC.
Previous meta-analyses have also failed to demonstrate
clinical beneﬁt of RIPC.42,43 However, two aspects of this
meta-analysis differentiate it from prior studies. First, this
analysis includes two recent, large, high-quality RCTs of
RIPC in patients undergoing cardiac surgery not included in
previous meta-analyses.15,16 The inclusion of these trials
increased the study population 2-fold. Second, as far as we
are aware, this is the ﬁrst meta-analysis to evaluate
outcomes as a function of propofol and K-ATP antagonist
use.
Although the mechanisms of RIPC have not been fully
elucidated, many believe there are components of both
humoral and sensory-neuronal pathways that confer organ
protection.44 The neuronal pathway was ﬁrst described by
Jones et al,45 who demonstrated that myocardial protection
could be produced through activation of sensory C ﬁbers by
an abdominal incision in mice. Furthermore, transection of the
spinal cord and blockade of sensory C ﬁbers by lidocaine
Figure 3. Subgroup analysis of cardiac surgeries performed with and without propofol anesthesia. The sizes of the squares
representing the point estimates for each study are proportional to the weight of the study. Diamonds indicate the overall risk ratio
(RR) and 95% CIs. RIPC indicates remote ischemic preconditioning.
Table 4. Subgroup Analysis of Perioperative Propofol Use
No. (RIPC) AKI (RIPC) No. (Sham) AKI (Sham) RR (95% CI) P Value
Propofol used (N=9 trials)13,15,16,20,21,28,30,32,33
1874 445 (23.7%) 1901 474 (24.9%) 0.928 (0.781–1.102) 0.39
Propofol not used (N=3 trials)3,11,25
217 71 (32.7%) 217 103 (47.5%) 0.700 (0.527–0.930) 0.014
AKI indicates acute kidney injury; RIPC, remote ischemic preconditioning; RR, risk ratio.
DOI: 10.1161/JAHA.116.004666 Journal of the American Heart Association 11




































abrogated the beneﬁt of preconditioning, suggesting neuronal
signal transmission. Similarly, propofol may disrupt mediators
of the neuronal pathway and diminish the clinical beneﬁts of
RIPC when compared with isoﬂurane anesthesia.14,46 Other
investigators have suggested propofol itself may be protective
and any incremental beneﬁts of RIPC are too small to be
detected.47 Our analysis is congruent with these theories, as
we observed a highly signiﬁcant reduction in AKI in the
subgroup of patients who did not receive propofol, despite no
beneﬁt in the overall cohort.
In addition to the neuronal pathway, humoral-mediated
pathways have also been described. After Huffman et al48
demonstrated that transfer of serum from preconditioned to
recipient rats prior to an induced MI conferred cardiac
protection, the mediators of this pathway were explored.
Adenosine and bradykinin, among other mediators, have
been shown to induce preconditioning of myocytes,
thought to be via the activation of the K-ATP channel
pathway.44,49,50 Loukogeorgakis et al51 implicated the K-ATP
pathway in IPC-mediated endothelial protection by demon-
strating abolition of the protective effect after administration
of glibenclamide, a K-ATP antagonist. In our subgroup
analysis, after removal of studies that included patients
treated with K-ATP antagonists, clinical beneﬁt of RIPC was
still not observed.
Study Limitations
The results of this meta-analysis should be interpreted with
consideration of its limitations. First, the majority of trials
included in the review were single-center studies with varying
inclusion and exclusion criteria. Second, deﬁnitions for
outcomes and duration of follow-up differed between included
trials. Third, because we assumed that all patients in a given
trial either did or did not receive propofol, a portion of patients
within individual trials may have been miscategorized. Addi-
tionally, variability in RIPC protocols may have led to
heterogeneity in the analysis. Finally, data were extracted
only from RCTs and may not be representative of patients
treated in usual practice.
Conclusions
RIPC does not prevent morbidity or mortality in patients
undergoing cardiac surgery with cardiopulmonary bypass. In
the subgroup of studies in which propofol was not used, a
reduction in AKI was seen, suggesting that propofol may
interact with the protective effects of RIPC. To evaluate the
independent effect of RIPC on outcomes, future studies on
RIPC should be performed in the absence of propofol
anesthesia.
Figure 4. Assessment of publication bias. This funnel plot is a plot of a measure of study size on the
vertical axis as a function of effect size on the horizontal axis for acute kidney injury. Large studies appear
toward the top of the graph and tend to cluster near the mean effect size. Smaller studies appear toward
the bottom of the graph and (since there is more sampling variation in effect size estimates in the smaller
studies) will be dispersed across a range of values. In the absence of publication bias, the studies,
represented by circles, are distributed symmetrically about the combined effect size. The dashed diamond
appearing below the x axis represents the summary effect.
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